NewsRoom Articles - Page 5 of 218

FridaySep 12, 2025 12:30 pm

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Company releases report updating status of proprietary 12-lead ECG synthesis software for arrhythmia assessment. Earlier this year, HeartBeam submitted its software application to the U.S. Food and Drug Administration. Plans will ensure that healthcare providers and patients can seamlessly integrate the HeartBeam system into clinical workflows and home-monitoring routines. In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness…

FridaySep 12, 2025 10:00 am

Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness

Researchers at University of Pittsburg have found that patients who consume sucralose regularly have a lower likelihood of benefiting from immunotherapy and having longer survival times. Sucralose is an artificial sweetener that is commonly used in a variety of diet products, such as Splenda. This research is the first to connect the dietary choices that people make to groundbreaking cancer treatments. For their study, the team obtained the dietary data of 91 patients diagnosed with advanced melanoma. They also obtained similar data from 41 patients having lung cancer. The patients whose daily intake of sucralose exceeded 0.07mg for each pound…

ThursdaySep 11, 2025 12:45 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Exclusive U.S. patent rights for computer-aided diagnosis (“CADx”) with breast CT secured through a global license with the University of California CADx planned as a post-market software upgrade, creating dual revenue streams via upgrade incentives and licensing Patent exclusivity paired with proprietary machine-learning reconstruction establishes a durable moat in dedicated breast imaging The AI Integration Challenge in Medical Imaging Artificial intelligence has long promised to revolutionize radiology, but most applications remain stuck between theoretical potential and real-world limitations. CADx systems can enhance detection, yet they face hurdles: lack of specialized datasets, workflow disruptions, and intellectual property barriers. In breast imaging,…

ThursdaySep 11, 2025 12:00 pm

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

Adageis provides AI-powered healthcare software designed to simplify value-based care adoption. The company’s patented ProActive Care Platform integrates with leading electronic health record (“EHR”) systems. The platform emphasizes simplicity, visibility into insurance contracts, and long-term financial gain for providers. Providers can use the system to identify high-value services, track reimbursements, and manage complex contracts. Adageis currently covers more than 260,000 patient lives, with ongoing growth expected. Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. By focusing on…

ThursdaySep 11, 2025 10:00 am

Kennedy’s MAHA Plan to Make Kids Healthier Receives Mixed Reactions

On Tuesday, the U.S. federal administration published a report aimed at improving the health of children in the country. The report calls for wide-ranging policy changes and executive actions to tackle the chronic disease burden rising in the country. HHS Secretary Kennedy Jr. announced this report. However, reactions to the contents of the report have been mixed. Speaking during the release, Kennedy hailed the 128 recommendations contained in the report as “unprecedented and historic” in addressing the “existential threat” posed by chronic diseases in American kids. Many researchers and experts say the report is rich in rhetoric but thin on…

WednesdaySep 10, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System

The system’s design emphasizes user friendliness and portability while aligning with the growing trend toward remote patient monitoring and telemedicine. HeartBeam to initiate commercial launch upon FDA clearance of 12-lead ECG synthesis software, anticipated later this year. For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart's electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart's…

WednesdaySep 10, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially…

TuesdaySep 09, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation. SNGX’s Specialized BioTherapeutics division is anchored by its proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for CTCL. Soligenix’s Public Health Solutions division positions the company as an important contributor to biodefense and emerging infectious disease. Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that…

TuesdaySep 09, 2025 10:00 am

Senior NIH Officials Allege Retaliation as Motive for Their Ouster

Two former officials at the NIH have filed whistleblower complaints in which they allege that their removal from office was a result of their resistance to giving politics priority over science and their efforts to defend vaccines and research grants. They filed their complaints last week. Back in April, Kathleen Neuzil and Jeanne Marazzo were put on administrative leave from their NIH top positions. In their complaints filed last week at the United States Office of Special Counsel, they claim that the work environment at the NIH after Robert F. Kennedy Jr. took over as HHS Secretary became hostile to…

MondaySep 08, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Nutriband sustains itself through multiple revenue-generating subsidiaries At the core of the company’s innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

Kennedy’s MAHA Plan to Make Kids Healthier Receives Mixed Reactions

HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

Senior NIH Officials Allege Retaliation as Motive for Their Ouster

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search